U-PVCT

Q:PVCT - PROVECTUS BIOPHARMACEUTICALS INC - https://www.pvct.com

23:33:52 EST

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
PVCT - Q	not subscribed					0.0384	-0.0036	-8.6	709.5	28	43	0.042 0.046 0.038	0.113 0.0386	15:59:00	Oct 09	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market: OTC Markets -- Tier: OTCQB -- Status: Active

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Portfolio

Recent Trades - Last 10 of 43

More trades...

Time ET	Ex	Price	Change	Volume
15:59:00	Q	0.0384	-0.0036	60,000
15:58:34	Q	0.038	-0.004	40,000
15:58:30	Q	0.038	-0.004	10,000
15:57:34	Q	0.0384	-0.0036	100,000
15:57:20	Q	0.0389	-0.0031	10,000
15:57:20	Q	0.04138	-0.00062	5,000
15:57:20	Q	0.0384	-0.0036	7,500
15:57:17	Q	0.0389	-0.0031	10,000
15:57:10	Q	0.0397	-0.0023	10,000
15:57:08	Q	0.04154	-0.00046	10,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2025-10-09 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
2025-09-29 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
2025-06-26 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer
2025-06-09 08:00	U:PVCT	News Release200	Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

Date ET

Symbol

Type

Headline

2025-10-09 08:00

U:PVCT

News Release

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy

2025-09-29 08:00

U:PVCT

News Release

Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer